Featured Stories
Latest company news, announcements, and milestones from 4baseCare.
4baseCare collaboration with East Ocyon Bio Private Limited
We’re super excited to collaborate with East Ocyon Bio Private Limited | Dr. Dinesh Kundu (MBBS, MBA) & Dr. Renu Kundu, bringing together complementary strengths in genomics, advanced assays, and cell & gene therapy research ! This collaboration is focused on identifying novel biomarkers and therapeutic possibilities from population-specific genomic insights. Some of the most meaningful healthcare innovations can be built in India, for Indian populations first and ultimately, for patients across the world. With aligned scientific vision, strong teams and a shared commitment to advancing precision medicine, we look forward to what this collaboration can uncover.
Scanning cancer up close, personal a revolution is underway in cancer diagnosis
A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Since the NGS test can be beyond the reach of many, a unique collaboration called LuNGS Alliance is making it free for lung cancer patients in India, offering a glimpse of how medical breakthroughs can be made accessible and affordable.
4baseCare expands cancer profiling panel with 2,206-gene Indiegene V2
4baseCare launches TARGT Indiegene V2, brings biology-first approach to comprehensive cancer profiling Five years after the launch of Indiegene V1, the next generation expands to 2,206 genes with most comprehensive coverage of Hallmarks of Cancer, HRD scoring and 36 HRR genes profiling, and 299 fusions, individualised Tumour Mutation Burden (iTMB) score with percentile scoring
4baseCare has partnered with Cancer Institute (WIA), Adyar, Chennai
4baseCare has partnered with Cancer Institute (WIA), Adyar, Chennai, to expand access to advanced genomic testing for cancer patients. The collaboration brings together the Institute’s patient-centric cancer care ecosystem with 4baseCare’s expertise in comprehensive genomic profiling and precision oncology. It is focused on enabling patients to access advanced molecular testing closer to where they receive care, with accessibility and affordability at the centre of the initiative.
OncoTwin winner of Best Innovation in AI Health -At the AI Bharat Health Mission 2026
As Healthcare moves into an AI-first future, the real opportunity lies in making innovation clinically meaningful, accessible, and built for the populations we serve.Grateful to the organizers of AI Bharat Health Mission 2026 and BioSpectrum for bringing together leaders, innovators, and healthcare changemakers on one platform.
4baseCare announces close of its Series B round at ₹130 Cr ($14 Mn).
4baseCare announces close of its Series B round at ₹130 Cr ($14 Mn), co-led by investors Ashish Kacholia and Lashit Sanghvi, with participation from existing backers Yali Capital, Infosys & growX ventures.
4baseCare is proud to be enabling the LuNGS alliance driven by CRSF - Cancer Research and Statistic Foundation and supported by pharma companies like AstraZeneca, Roche, Eli Lilly and Company, Johnson & Johnson , Pfizer and Bristol Myers Squibb.
"It's not just about being good in science or the business, it's about how each and every life counts and doing our part towards the same.” - Kshitij Rishi. 4baseCare is proud to be enabling the LuNGS alliance driven by CRSF - Cancer Research and Statistic Foundation and supported by pharma companies like AstraZeneca, Roche, Eli Lilly and Company, Johnson & Johnson , Pfizer and Bristol Myers Squibb. We thank The Economic Times for the coverage.
